Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female patients, ≥50 years of age with signed informed consent before study procedures~* Visual impairment predominantly due to nAMD.~* Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by fluorescein angiography (FA) and/or color fundus photography~* Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT~* BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate Snellen equivalent of 20/32 and 20/320)~Key Exclusion Criteria:~* Any type of advanced, severe or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.~* Stroke or myocardial infarction within 3 months prior to Screening.~* Any active periocular or ocular infection or inflammation in both eyes.~* Ocular disorders in the study eye at the time of enrollment that may confound interpretation of study results and compromise visual acuity.~* Presence of amblyopia or amaurosis in the fellow eye.~* History of treatment with any anti-angiogenic drugs (including any anti- vascular endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab \[Avastin®\], aflibercept \[Eylea®\]) or vPDT in the study eye.~* History of intravitreal treatment with corticosteroids within 6 months and history of intra-ocular surgery within 3 months in the study eye prior to the Screening.~* Pregnant or nursing (lactating) women. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I ranibizumab 0.5 mg monthly (Type: ACTIVE_COMPARATOR): Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
- Group II ranibizumab 0.5 mg TER (Type: ACTIVE_COMPARATOR): Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11

Based on this trial design, predict the completion outcome and termination type (if applicable).